Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence ...

MoonLake Immunotherapeutics has secured up to $500 million in non-dilutive financing from Hercules Capital, bolstering its ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

European Valuations and Interpath Advisory Limited, acting on behalf of the liquidators of Surepharm Services Limited, is ...

The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...